t-cells

Documents about t-cells

• Short-chain fatty acids modulate regulatory T cells via NF-κB signaling pathway in a rat model of spinal cord injury.#265468NCBI PubMed Central
• Identification of Prognostic Genes Relevant With the Nuclear Factors of Activated T Cells Based on Transcriptomics in Oral Squamous Cell Carcinoma.#385177NCBI PubMed Central
• Margin-enriched CD4(+) central-memory T cells affect macrophages via ANXA1-FPR1 signaling axis to promote tumor progression in intrahepatic cholangiocarcinoma.#653419NCBI PubMed Central
• BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma#827806ClinicalTrials.gov
• Relmacabtagene Autoleucel in Hematologic Malignancies#832124ClinicalTrials.gov
• Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma#850644ClinicalTrials.gov
• Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients#880293ClinicalTrials.gov
• A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)#900000ClinicalTrials.gov
• Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia#900865ClinicalTrials.gov
• Infliximab, Regulatory T Cells, IL2 and Crohn's Disease#906262ClinicalTrials.gov
• FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia#979471ClinicalTrials.gov
• Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC#1008641ClinicalTrials.gov
• Evolving role of CD8(+) tissue-resident memory T cells in autoimmune and immune mediated inflammatory diseases: linking pathogenesis to therapeutic approaches.#1054165NCBI PubMed Central
• Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma#121360ClinicalTrials.gov
• Supplementary Figure S1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246359Figshare
• Supplementary Figure S2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246360Figshare
• Supplementary Figure S3 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246361Figshare
• Supplementary Figure S4 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246362Figshare
• Supplementary Figure S5 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246363Figshare
• Supplementary Figure S6 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246364Figshare
• Supplementary Figure S7 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246365Figshare
• Supplementary Figure S8 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246366Figshare
• Supplementary Table 1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246367Figshare
• Supplementary Table 2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246368Figshare
• Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.#318769Dipòsit Digital de la Universitat de Barcelona
• CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors#1044888ClinicalTrials.gov
• In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies#800465ClinicalTrials.gov
• Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas#857285ClinicalTrials.gov
• T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia#851126ClinicalTrials.gov
• GD2-CAR T Cells for Pediatric Brain Tumours#801382ClinicalTrials.gov
• Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation#801495ClinicalTrials.gov
• A Study of MCARH109 and MCARH125 in People With Multiple Myeloma#899527ClinicalTrials.gov
• A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy#992506ClinicalTrials.gov
• Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma#1044894ClinicalTrials.gov
• Dietary conjugated linoleic acid enhances resistance to Salmonella infection by promoting PPARγ-mediated metabolic reprogramming and effector function in CD8⁺ T cells.#13645NCBI PubMed Central
• Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma#140978ClinicalTrials.gov
• Mathematical modeling and sensitivity analysis of synNotch-CAR T-cells identify engineering targets for dynamic tunability#149900Unpaywall
• The HIV-2 reservoir: lessons from HIV-1 and knowledge gaps#161367HAL (France)
• Multidimensional single-cell analysis of the molecular characteristics and functional pathways of Regulatory T cells in the microenvironment of HR+ breast cancer.#227876NCBI PubMed Central
• CLEC2B-KLRB1 axis acts as an immune checkpoint, governing the exhaustion of CD8(+) T cells and their resistance to immune checkpoint blockade.#251063NCBI PubMed Central
• C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)#267996ClinicalTrials.gov
• Distinct SIV-specific CD8+ T cells in the lymph node exhibit simultaneous effector and stem-like profiles and are associated with limited SIV persistence#284310HAL (France)
• Identifying The Effect Of Biosynthesized Agnp From Garcinia Atroviridis Aqueous Extract On Induced T-regulatory Cells From Non-obese Resistance (Nor) Mouse Model#407419USM Repository
• Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma#426784ClinicalTrials.gov
• BDNF improves the survival of mesenchymal stem cells cultured on pre-structured gelatin material containing strontium and calcium phosphates for bone regeneration#476223JLUpub
• A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma#826745ClinicalTrials.gov
• EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma#847827ClinicalTrials.gov
• Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)#865765ClinicalTrials.gov
• Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma#914570ClinicalTrials.gov
• Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma#915980ClinicalTrials.gov